Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2021-05-20 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1926 characters) and contains the header 'RNS Number : 2814Z'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. This type of immediate, short-form regulatory update that doesn't fit a specific financial reporting category (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing, which corresponds to the RNS code. It is not an announcement of a report publication (RPA) but a direct market operational notice.
2021-05-20 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1909 characters) and contains the header 'RNS Number : 2809Z' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Price Monitoring Extension' for a security, which is a specific, brief operational announcement related to trading on the exchange, rather than a comprehensive financial report (like 10-K or IR) or a standard corporate action (like DIV or ER). Since it is a general regulatory announcement disseminated via the RNS system that doesn't fit into the more specific categories (like DIRS, MANG, or DIV), it falls best under the 'Regulatory Filings' fallback category, which is often used for miscellaneous exchange notices.
2021-05-20 English
Operations Update
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states 'This information is provided by RNS, the news service of the London Stock Exchange.' RNS filings are general regulatory announcements. The content is an 'Operations Update' detailing progress on MTAs, in vivo studies, and personnel, which is typical for a timely operational update rather than a comprehensive annual report (10-K), quarterly report (IR), or earnings release (ER). Since it is a general regulatory announcement that doesn't fit the more specific categories like DIV, DIRS, or MANG, the appropriate fallback category is Regulatory Filings (RNS). The document length (7045 chars) is substantial enough that it is the primary announcement itself, not just a notice of publication (RPA).
2021-05-20 English
Appointment of Chief Medical Officer
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 4916W' and contains information about the appointment of a new Chief Medical Officer, effective May 1, 2021. This is a specific corporate announcement regarding management change. The definition for Board/Management Information (MANG) covers 'Announcement of changes in the company's board of directors or senior management.' The presence of the RNS distribution footer further confirms it is a regulatory news service announcement, but the content is specifically about management change, making MANG the most precise classification over the general RNS fallback.
2021-04-26 English
Publication on sulforaphane in COVID-19
Legal Proceedings Report Classification · 1% confidence The document begins with 'RNS Number : 5753U' and contains contact information typical of a press release distributed via the Regulatory News Service (RNS). The content discusses a scientific publication related to the company's drug candidate (SFX-01) and COVID-19, which is an update on company activity but not a formal financial report (like 10-K or IR) or a specific corporate action (like DIV or CAP). The footer explicitly states, 'Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature.' This strongly suggests it is a general announcement or press release that doesn't fit the highly specific financial filing codes. Therefore, the most appropriate classification is the general regulatory/news announcement fallback, RNS.
2021-04-07 English
Result of AGM
AGM Information Classification · 1% confidence The document explicitly states it is announcing the 'Result of Annual General Meeting' and provides a detailed table showing the 'Results of the proxy voting for the AGM'. This directly corresponds to the definition of AGM Information (AGM-R). Although it contains voting results, the primary context is the outcome of the Annual General Meeting itself, making AGM-R the most precise fit over DVA (Declaration of Voting Results & Voting Rights Announcements), which is usually a standalone announcement of results without the context of the meeting announcement itself. The document is short and is a direct announcement, not a proxy statement or a full annual report.
2021-03-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.